Abstract
In vitro immunological and biological activity of four commercially available preparations of human chorionic gonadotropin (hCG) for clinical use (Predalon®: hCG-A, Primogonyl®: hCG-B, Choragon®: hCG-C and Pregnisin®: hCG-D) were examined. The methods used include immunoassay, cAMP production in Chinese hamster ovary (CHO) cells and structural analysis of hCG with high performance liquid chromatography (HPLC). There were remarkable differences in immunological activities among preparations. hCG-D had the highest concentration of free hCGβ. In CHO cells, production of cAMP with hCG-C was significantly higher than that with other preparations. Analyses in HPLC showed similar pattern in hCG-C and a standard preparation of hCG (CR 123). The highest immunological activity in hCG-A could be attributed to the presence of nicked form of hCG in this preparation. Various hCG components in preparation may explain these differences.
Zusammenfassung
Vier für den klinischen Einsatz kommerziell erhältliche Human-Choriongonadotropin(hCG)-Präparate (Predalon®: hCG-A, Primogonyl®: hCG-B, Choragon®: hCG-C und Pregnisin®: hCG-D) wurden in vitro sowohl auf ihre immunologische als auch biologische Aktivität untersucht. An Methoden wurden dabei eingesetzt: verschiedene Immunoassays, die Messung der cAMP-Antwort in Chinesischen Hamster Ovar (CHO) Zellen und zur Strukturanalyse eine High Performance Liquid Chromatography (HPLC). Die Präparate ließen große Unterschiede in ihren immunologischen Aktivitäten erkennen. HCG-D wies dabei die höchste Konzentration an freiem hCGβ auf. HCG-C zeigte die signifikant stärkste biologische Aktivität, gemessen an der in CHO-Zellen induzierten cAMP-Produktion. HCG-C erwies sich strukturell bei der HPLC-Analyse als der Standardpräparation (hCG CR123) ähnlich. Die Anwesenheit von sog. „nicked” hCG-Formen in der hCG-A Präparation konnte mit der höchsten immunologischen Aktivität in Beziehung gesetzt werden. Die unterschiedliche Zusammensetzung von kommerziell verfügbaren hCG-Präparaten mit Auftreten von Variantformen des hCG-Moleküls führt offensichtlich zu Unterschieden in der immunologischen und biologischen Aktivität der Substanzen, die auch für den Kliniker bedeutsam sein könnten.
Key words
hCG - Commercial preparation - CHO cells - HPLC
Schlüsselwörter
HCG - Kommerzielle Präparate - CHO-Zellen - HPLC
References
1
Alfthan H, Stenman U H.
Pathophysiological importance of various molecular forms of human choriogonadotropin.
Mol Cell Endocrinol.
1996;
125
107-120
2
Birken S, Kovalevskaya G, O'Connor J.
Metabolism of hCG and hLH to multiple urinary forms.
Mol Cell Endocrinol.
1996;
125
121-131
3
Cole L A.
Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites.
Clin Chem.
1997;
43
2233-2243
4
Diaz-Cueto L, Barrios-de-Tomasi J, Timossi C, Mendez J P, Ulloa-Aguirre A.
More in-vitro bioactive, shorter lived human chorionic gonadotropin charge isoforms increases at the end of the first and during the third trimesters of gestation.
Mol Hum Reprod.
1996;
2
643-650
5
Hoermann R, Keutmann H AT, Amir S M.
Carbohydrate modifications transform human chorionic gonadotropin into a potent stimulator of adinosine 3′,5′ monophosphate and growth responses in FRTL-5 thyroid cells.
Endocrinology.
1991;
128
1129-1135
6
Hoermann R, Broecker M, Grossmann M, Mann K, Derwahl M.
Interaction of human chorionic gonadotropin (hCG) and asialo-hCG with recombinant human thyrotropin receptors.
J Clin Endocrinol Metab.
1994;
78
933-938
7
Hoermann R, Poertl S, Liss I, Amir S M, Mann K.
Variation in the thyrotropic activity of human chorionic gonadotropin in Chinese hamster ovary cells arises from differential expression of the human thyrotropin receptor and microheterogeneity of the hormone.
J Clin Endocrinol Metab.
1995;
80
1605-1610
8
Kardana A, Cole A.
The stability of hCG and free β in serum samples.
Prenat Diagn.
1997;
17
141-147
9
Nagy A M, Glinoer D, Picelli G, Delogne-Desnoeck J, Fleury B, Courte C. et al .
Total amounts of circulating human chorionic gonadotropin alpha and beta subunits can be assesed throughout human pregnancy using immunoradiometric assays calibrated with the unaltered and thermally dossociated heterodimer.
J Endocrinol.
1994;
140
513-520
10
Norman R J, Buchholz M M, Somogyi A A, Amato F.
hCGβ core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG.
J Endocrinol.
2000;
164
299-305
11
Okamoto T, Niu R, Matsuo K, Furuhashi M, Ohsawa M, Mizutani S, Suzuki H.
Human chorionic gonadotropin beta-core fragment ist directly produced by cancer cells.
Life Sci.
2001;
68
861-872
12
Perret J, Ludgate M, Libert F, Gerard C, Dumont J E, Vasser G. et al .
Stable expression of human TSH receptor in CHO cells and characterization of differentially expressing clones.
Biochem Biophys Res Commun.
1990;
171
1044-1050
13
Poertl S, Liss I, Mann K, Hoermann R.
Crude urinary human chorionic gonadotropin contains variant forms of hCG with low sialic acid content that exhibit an increased thyrotropic activity in CHO cells expressing the human TSH receptor.
Exp Clin Endocrinol.
1995;
103
168-174
14
Vitti P, Elisei R, Tonacchera M, Chiovato L, Mancusi F, Rago T. et al .
Detection of thyroid stimulation antibody using Chinese hamster ovary cells transfected with the cloned human thyrotropin receptor.
J Clin Endocrinol Metab.
1993;
76
499-503
15
Wide L, Lee J Y, Rasmussen C.
A change in the isoforms of human chorionic gonadotropin occurs around the 13th week of gestation.
J Clin Endocrinol Metab.
1994;
78
1419-1423
Keiichi KatoMD
Frankenstraße 252
45134 Essen, Germany
Phone: (49)-2 01-44 32 70
Fax: (49)-2 01-4 30 64 59
Email: praxis@drkato.de